On this week’s Tech Nation, James Vincent about his book, “Beyond Measure: The Hidden History of Measurement from Cubits to Quantum Constants”, and our age-old propensity as humans … to measure things. Then Dr. Rob Ross from Surface Oncology tells us why the first generation of immuno-oncology drugs only worked on 15% of cancer patients, and how Surface Oncology is tackling the other 85%. Their Phase 2 trials in lung cancer and liver cancer are recruiting now.
